JPH01272600A - Differentiation-inducing factor - Google Patents
Differentiation-inducing factorInfo
- Publication number
- JPH01272600A JPH01272600A JP10019088A JP10019088A JPH01272600A JP H01272600 A JPH01272600 A JP H01272600A JP 10019088 A JP10019088 A JP 10019088A JP 10019088 A JP10019088 A JP 10019088A JP H01272600 A JPH01272600 A JP H01272600A
- Authority
- JP
- Japan
- Prior art keywords
- differentiation
- human
- derived
- inducing
- inducing factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 title claims abstract description 20
- 102100032352 Leukemia inhibitory factor Human genes 0.000 title claims abstract description 20
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 14
- 230000001939 inductive effect Effects 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims abstract description 10
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 9
- 239000012228 culture supernatant Substances 0.000 claims abstract description 9
- 210000004072 lung Anatomy 0.000 claims abstract description 9
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims abstract description 5
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims abstract description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims abstract description 5
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims abstract description 4
- 238000001155 isoelectric focusing Methods 0.000 claims description 8
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 3
- 201000006845 reticulosarcoma Diseases 0.000 claims description 3
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 3
- 230000001766 physiological effect Effects 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 abstract description 9
- 238000002523 gelfiltration Methods 0.000 abstract description 8
- 238000004366 reverse phase liquid chromatography Methods 0.000 abstract description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract description 5
- 229910052588 hydroxylapatite Inorganic materials 0.000 abstract description 5
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 abstract description 5
- 239000000741 silica gel Substances 0.000 abstract description 5
- 229910002027 silica gel Inorganic materials 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 3
- 239000006228 supernatant Substances 0.000 abstract description 3
- 239000012980 RPMI-1640 medium Substances 0.000 abstract description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 239000001963 growth medium Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 210000003003 monocyte-macrophage precursor cell Anatomy 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical class O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000872 buffer Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000006894 monocytic leukemia Diseases 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102100029350 Testis-specific serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 101710116855 Testis-specific serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、少な（とも、ヒト組織球性リンパ腫由来の単
芽球性株細胞［１−９３７およびヒト急性単球性白血病
株細胞ＴＨＰ−１に対して分化誘導活性を有する新規な
蛋白質に関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a monoblastic cell line derived from human histiocytic lymphoma [1-937] and a human acute monocytic leukemia cell line THP- The present invention relates to a novel protein having differentiation-inducing activity against 1.
骨髄性・単球住白血病患者から株化された種々の白血病
細胞株（ＭＬ−１，）ＩＬ−６０，Ｕ−９３７，ＴＨＰ
−１）は生体が産生ずる蛋白質分化誘導因子によりイン
ビトロで成熟細胞（マクロフｉ−ジ／頚粒球〉に分化誘
導される。Various leukemia cell lines (ML-1,) IL-60, U-937, THP established from myeloid/monocytic leukemia patients
-1) is induced to differentiate into mature cells (macrophages/cervical granulocytes) in vitro by a protein differentiation-inducing factor produced by the living body.
そして、これらの株化細胞を標的に分化誘導活性を有す
る蛋白質因子が探索され、ヒト末梢血白血球やヒト培養
細胞の培養上清がら数種の分化誘導因子の存在が明らか
になっている（特開昭６０−２８９３４、同６２−１６
９７３１ 、特願昭６１−２０３８８４ ）。Protein factors with differentiation-inducing activity have been searched for targeting these established cell lines, and the existence of several differentiation-inducing factors has been revealed in the culture supernatants of human peripheral blood leukocytes and human cultured cells. Kaisho 60-28934, Kaisho 62-16
9731, patent application No. 61-203884).
今回、ヒト肺由来線維芽細胞の培養上清中に従来より既
知の分化誘導因子とは異なる、新規な分化誘導因子が存
在することを見出し、これを単一蛋白にまで高度精製し
、その性状を明らかにした。This time, we discovered that a novel differentiation-inducing factor different from previously known differentiation-inducing factors exists in the culture supernatant of human lung-derived fibroblasts, highly purified it to a single protein, and characterized its properties. revealed.
本発明の分化誘導因子はヒト肺由来線維芽細胞の培養上
清中に存在する蛋白質であり、以下の性質を有する。The differentiation-inducing factor of the present invention is a protein present in the culture supernatant of human lung-derived fibroblasts, and has the following properties.
（ａ）分子量：２５０００±２０００
（還元下、ＳＤＳ−ＰＡＧＥ法による）（ｂ）等電点：
ｐＩ５．４±０．２
（等電点クロマトグラフィーによる）
（ｃ） Ｎ末端アミノ酸配列：
ＶａｌＰｒｏＰｒｏＧ１ｙＧ１ｕＡｓｐＳｅｒＬｙｓＡ
ｓｐＶａｌＡ１ａ＾１ａＰｒｏＸＡｒｇＧｌｎＸ１ｅｕ
−
（Ｘは未同定）
（ｄ）生理活性：
少なくとも、ヒト組織球性リンパ腫由来の単芽球性株細
胞ｔｌ−９３７およびヒト急性単球性白血病株細胞ＴＨ
Ｐ−１に対して分化誘導活性を有する。(a) Molecular weight: 25000±2000 (under reduction, by SDS-PAGE method) (b) Isoelectric point:
pI5.4±0.2 (by isoelectric focusing chromatography) (c) N-terminal amino acid sequence: ValProProG1yG1uAspSerLysA
spValA1a^1aProXArgGlnX1eu
- (X is unidentified) (d) Physiological activity: At least human histiocytic lymphoma-derived monoblastic cell line tl-937 and human acute monocytic leukemia cell line TH
It has differentiation-inducing activity against P-1.
（ｅ）比活性： ５ ＸＩＯ” 〜１ＯｘｌＱ’ｕｎｉ
ｔｓ／ｍｇ蛋白本発明の分化誘導因子は以下のような方
法で調製される。(e) Specific activity: 5XIO" ~ 1OxlQ'uni
ts/mg protein The differentiation-inducing factor of the present invention is prepared by the following method.
（原料細胞）
ヒト肺由来線維芽細胞として、好ましくは、ヒト肺由来
正常線維芽細胞をＳＶ４０等のウィルスで形質転換して
樹立した株化細胞Ｗｌ−２６ＶＡ４などを用いる。(Raw material cells) As human lung-derived fibroblasts, preferably used is the established cell line Wl-26VA4, which is established by transforming human lung-derived normal fibroblasts with a virus such as SV40.
（培養条件）
培地としては、例えばＲＰＭＩ−１６４０、ダルベツコ
（Ｄｕｌｂｅｃｃｏｏｓ） ＭＥＭ 、イーグルＭＥＭ
培地等が用いられ、当該培地中には０〜１０％の牛胎児
血清を添加してもよい。(Culture conditions) Examples of the medium include RPMI-1640, Dulbeccoos MEM, Eagle MEM.
A medium or the like is used, and 0 to 10% fetal bovine serum may be added to the medium.
培養温度は、室温〜３７℃（好適には３７℃）が好まし
く、さらに００２１〜１０％（好適には５％）、飽和水
蒸気中で培養されることが好ましい。培養時間は、通常
２〜７日間程度であり、その後、培養上清を回収する。The culture temperature is preferably room temperature to 37°C (suitably 37°C), and it is further preferable that the culture is carried out in saturated steam at a temperature of 0021 to 10% (preferably 5%). The culture time is usually about 2 to 7 days, and then the culture supernatant is collected.
この培養上滑中に、本発明の分化誘導因子が産生されて
いる。The differentiation-inducing factor of the present invention is produced in this culture medium.
（精 製）
培養上清から本発明の分化誘導因子の精製する方法とし
ては、公知の方法、すなわち、遠心分離、透析、限外濾
過、塩析、ゲル濾過、吸着クロマト、等電点クロマト、
逆相クロマト等を適宜組合せることにより行なわれる。(Purification) Methods for purifying the differentiation-inducing factor of the present invention from the culture supernatant include known methods, such as centrifugation, dialysis, ultrafiltration, salting out, gel filtration, adsorption chromatography, isoelectric focusing chromatography,
This is carried out by appropriately combining reverse phase chromatography and the like.
具体的には以下のように行なわれる。Specifically, this is carried out as follows.
■シリカゲル処理
培養上清をシリカゲルに接触させ、吸着画分を回収する
。■Silica gel treatment The culture supernatant is brought into contact with silica gel and the adsorbed fraction is collected.
吸着時にはｐＨ６〜８の緩衝液（例えば、リン酸ｕ！街
液など）、溶出時には２０〜６０％エチレングリ゛コー
ル、０．１〜２Ｍ塩化ナトリウムを含むｐｔ（６〜８の
緩衝液（例えば、リン酸緩衝液など）を用いる。For adsorption, use a pH 6-8 buffer (e.g., phosphoric acid u! street solution, etc.); for elution, use a PT (6-8 pH buffer) containing 20-60% ethylene glycol and 0.1-2M sodium chloride (e.g. , phosphate buffer, etc.).
■ハイドロキシアパタイト処理
■の溶出画分をハイドロキシアパタイトに接触させ、吸
着画分を回収する。(2) Hydroxyapatite treatment The eluted fraction (2) is brought into contact with hydroxyapatite, and the adsorbed fraction is collected.
吸着時にはｐＨ６〜８の緩衝液（例えば、リン酸緩衝液
など）、溶出時にはｐＨ６〜８、塩濃度０．０１〜ＩＭ
の直線型濃度勾配による緩衝液（例えば、リン酸緩衝液
など）を用いる。Buffer with pH 6-8 (e.g. phosphate buffer) during adsorption, pH 6-8 with salt concentration 0.01-IM during elution.
A linear concentration gradient buffer (eg, phosphate buffer, etc.) is used.
■ゲル濾過 ■の溶出画分をゲル濾過処理し、活性画分を回収する。■Gel filtration The eluted fraction (2) is subjected to gel filtration and the active fraction is collected.
ゲル濾適用担体としてはデキストラン系、ポリアクリル
アミド系、アガロース系、ポリスチレン系、ポリ酢酸ビ
ニル系等が挙げられる。溶出時には、０．１〜０．２Ｍ
塩化ナトリウムを含むｐＨ６〜８の緩衝液（例えば、リ
ン酸緩衝液など）を用Ｉｌ）る。Examples of carriers applicable to gel filtration include dextran-based, polyacrylamide-based, agarose-based, polystyrene-based, and polyvinyl acetate-based carriers. During elution, 0.1-0.2M
A buffer containing sodium chloride and having a pH of 6 to 8 (eg, phosphate buffer, etc.) is used.
■等電点クロマト
■の溶出画分を等電点クロマト処理し、活性画分を回収
する。(2) Isoelectric focusing chromatography The eluted fraction of (2) is subjected to isoelectric focusing chromatography and the active fraction is collected.
等電点クロマト用担体としては陰イオン交換体（例えば
モノ−Ｐなど）等が挙げられる。接触時にはｐＨ６〜８
の緩衝液（例えば、イミダゾール−塩酸緩衝液など）を
、溶出時にはｐＨ３〜５の緩衝液（例えば、ポリバッフ
ァー７４−塩酸など）１こより形成されるｐＨ３〜８の
直線型ｐ）Ｉ勾配を用しする。Examples of the carrier for isoelectric focusing chromatography include anion exchangers (eg, mono-P, etc.). pH 6-8 upon contact
A linear p)I gradient of pH 3 to 8 formed from one buffer of pH 3 to 5 (such as Polybuffer 74-HCl) is used for elution. I'll do it.
■逆相クロマト
■の溶出画分を逆相クロマトで処理し、活性画分を回収
する。(2) Reverse phase chromatography The eluted fraction of (2) is treated with reverse phase chromatography and the active fraction is collected.
逆相クロマト用担体としてはＣ１系、ｃ、系、ｏＤｓ系
等が挙げられる。接触時にはｐＨ１〜３の溶媒（例えば
、トリフルオロ酢酸など）を、溶出時には、０〜８０％
のアセトニトリルを含むｐＨ１〜３の溶媒（例えば、ト
リフルオロ酢酸など）を用いる。Examples of carriers for reverse phase chromatography include C1 type, c, type, oDs type, and the like. A solvent with a pH of 1 to 3 (e.g., trifluoroacetic acid, etc.) is used during contact, and a solvent with a pH of 0 to 80% is used during elution.
A solvent having a pH of 1 to 3 (for example, trifluoroacetic acid, etc.) containing acetonitrile is used.
この場合、好ましくは、アセトニトリル□％から８０％
までの直線濃度勾配を用いる。In this case, preferably acetonitrile □% to 80%
Use a linear concentration gradient up to
なお、上記の回収方法は本発明細胞分化誘導物質回収の
一例を示したにすぎず、勿論性の方法によって回収して
もよい。It should be noted that the above-mentioned recovery method is merely an example of the recovery of the cell differentiation-inducing substance of the present invention, and it goes without saying that recovery may be performed by any other method.
かくして得られた分化誘導因子は単球性白血病細胞に対
して細胞分化誘導作用を示すものであり、化学用、薬理
学用の試薬として、また医薬品としても使用される。医
薬品として使用する場合には医薬品製造の通例技術にし
たがって、要すれば加熱処理、除菌濾過、凍結乾燥、分
注、製剤化を行えばよく、かくして新規な分化誘導因子
を含有する医薬品が提供される。The differentiation-inducing factor thus obtained exhibits a cell differentiation-inducing effect on monocytic leukemia cells, and is used as a reagent for chemistry and pharmacology, and as a pharmaceutical. When used as a pharmaceutical, heat treatment, sterile filtration, freeze-drying, dispensing, and formulation may be carried out according to conventional pharmaceutical manufacturing techniques, thus providing a pharmaceutical containing a novel differentiation-inducing factor. be done.
本発明をより詳細に説明するために、実施例を挙げるが
、本発明はこれらによって何ら限定されるものではない
。Examples will be given to explain the present invention in more detail, but the present invention is not limited thereto.
実施例
（１）分化誘導活性の測定
ヒト組織球性白血病細胞１１−９３７ を用いたＮＯＴ
還元活性（特開昭６２−２５１６６４参照）で測定し
た。また他の骨髄性白血病細胞（ＭＬ−１、ＴＨＰ−１
）についても同様の活性を調べた。 活性の算出は以下
の通りである。Example (1) Measurement of differentiation-inducing activity NOT using human histiocytic leukemia cells 11-937
It was measured by reducing activity (see JP-A-62-251664). In addition, other myeloid leukemia cells (ML-1, THP-1
) was also examined for similar activity. Calculation of activity is as follows.
最大吸光度を示す分化誘導因子標品をスタンダードとし
て用い、その５０％吸光度値を示す活性を１ ｕｎｉｔ
とする。そして被検サンプルを段階希釈して未分化細胞
と培養し、ＮＢＴ反応後の吸光度を測定してスタンダー
ドの５０％吸光度値を示すところの被検サンプルの最大
希釈倍数を活性単位とする。Using the differentiation-inducing factor preparation showing the maximum absorbance as a standard, the activity showing the 50% absorbance value was measured as 1 unit.
shall be. Then, the test sample is serially diluted and cultured with undifferentiated cells, and the absorbance after the NBT reaction is measured, and the maximum dilution of the test sample that shows an absorbance value of 50% of the standard is taken as the activity unit.
（２）産 生
ヒト正常線維芽細胞をＳＶ４０でトランスフオームし樹
立した株化細胞旧−２６Ｖ＾４（大日本製薬より購入）
を、アミノ酸溶液及びビタミン溶液を二倍濃度添加した
１０％牛脂児血清含有イーグルＭＥＭ培地にツスイ製）
で３７℃、７日間培養し上清を採取した。(2) Production Cell line Old-26V^4 established by transforming normal human fibroblasts with SV40 (purchased from Dainippon Pharmaceutical)
(manufactured by Tsusui) in Eagle MEM medium containing 10% tallow baby serum supplemented with amino acid solution and vitamin solution at twice the concentration.
The cells were cultured at 37°C for 7 days, and the supernatant was collected.
（３）ｆｉ製
（ｉ） シリカゲル処理
培養上清を遠心（３０００ｒｐｌｎ 、 １５分）後、
限外濾過（分画分子量１万カツト）シた。リン酸緩衝液
（ｐ）ｌ ７ ）で平衡化したシリカゲルを添加し、４
℃で一夜攪拌した。上清を除去した後、５６％エチレン
グリコール、１Ｍ塩化ナトリウム含有リン酸緩衝液（ｐ
）Ｉ ７ ）を用いて４℃で３時間攪拌し、溶出画分を
回収した。(3) Fi (i) After centrifuging the silica gel-treated culture supernatant (3000 rpm, 15 minutes),
Ultrafiltration (molecular weight cut off: 10,000 cuts) was carried out. Add silica gel equilibrated with phosphate buffer (p)l 7 ),
Stir overnight at °C. After removing the supernatant, phosphate buffer containing 56% ethylene glycol and 1M sodium chloride (p
) I 7 ) at 4° C. for 3 hours, and the eluted fractions were collected.
（ｉｉ）ハイドロキシアパタイト処理
（ｉ）の溶出画分を１０１１１Ｍ ’ｌｌ醋酸カリウム
緩衝液（ｐＨ６，８）で透析後、同緩衝液で平衡化した
ハイドロキシアパタイトに供した。溶出は０．０１〜０
．５Ｍ’Ｊン酸１カリウム緩衝液（ｐＨ６，８）の直線
型濃度勾配により行い、活性画分を回収した。(ii) Hydroxyapatite treatment The eluted fraction from (i) was dialyzed against 10111M'll potassium acetate buffer (pH 6,8) and then applied to hydroxyapatite equilibrated with the same buffer. Elution is 0.01-0
．． The reaction was carried out using a linear concentration gradient of 5M'J monopotassium phosphate buffer (pH 6, 8), and the active fraction was collected.
（ｉｉｉ）ゲル濾過
（ｉｉ）の溶出画分を、０．１５Ｍ塩化ナトリウム含有
０．１Ｍリン酸ナトリウム緩衝液（ｐ）Ｉ ７ ） で
平衡化したポリスチレン系ゲル濾過用カラム（ＴＳＫ−
Ｇ３０００ＳＷ 、東洋曹達社製）に供した。溶出は同
じ緩衝液を用い、活性画分を回収した。(iii) The eluate fraction of gel filtration (ii) was equilibrated with a 0.1M sodium phosphate buffer (p) I 7 ) containing 0.15M sodium chloride (TSK-1).
G3000SW, manufactured by Toyo Soda Co., Ltd.). The same buffer was used for elution, and active fractions were collected.
（ｉｖ ）等電点クロマト
（ｉｉｉ ）の溶出画分を２５ｍＭイミダゾール−塩酸
緩衝液（ｐＨ７，４）に対して透析した後、同じ緩衝液
で平衡化した陰イオン交換体（Ｍｏｎｏ Ｐ、 ファ
ルマシア社製）に供した。溶出はポリバッファー７４−
塩酸（ｐＨ４、ファルマシア社製）を流すことにより形
成されるｐＨ７，４から３．７の直線型ｐＨ勾配により
行い、活性画分を回収した。(iv) The eluted fraction of isoelectric focusing chromatography (iii) was dialyzed against 25 mM imidazole-hydrochloric acid buffer (pH 7,4), and then anion exchanger (Mono P, Pharmacia) equilibrated with the same buffer was used. (manufactured by). Elution was performed using polybuffer 74-
The reaction was carried out using a linear pH gradient from pH 7.4 to 3.7 formed by flowing hydrochloric acid (pH 4, manufactured by Pharmacia), and the active fraction was collected.
（ｖ）逆相クロマト
（ｉｖ）の溶出画分を、０．１％トリフルオロ酢酸（ｐ
Ｈ２）で平衡化したＣ２系逆相用カラム（Ｂａｋｅｒｂ
ｏｎｄ ＷＰ−Ｃ４、Ｊ、Ｔ、ベーカー社製）に供した
。溶出は０〜８０％アセトニトリル含有０．１％トリフ
ルオロ酢酸（ｐＨ２）を用いた直線型濃度勾配で行い、
活性画分を回収した。(v) The eluate fraction of reverse phase chromatography (iv) was converted to 0.1% trifluoroacetic acid (p
C2-based reverse phase column (Bakerb H2) equilibrated with
ond WP-C4, J, T, manufactured by Baker Company). Elution was performed with a linear concentration gradient using 0.1% trifluoroacetic acid (pH 2) containing 0-80% acetonitrile.
The active fraction was collected.
精製結果を第１表に示す。The purification results are shown in Table 1.
（４）性 状
（ｉ）分子量
ＳＤＳ−ＰＡＧＥ法
本発明の分化誘導因子の一部（約０．５μｇ相当）を２
％ＳＯＳ、 ０．３Ｍ ５ｕｃｒｏｓｅ含有０．０６２
５Ｍ ）リス−ＨＣｌバッファー、ｐＨ６，８或いは同
バッファーに２％２−メルカプトエタノールを含んだバ
ッファーを添加し溶解して、室温で約３０分く前者バッ
ファー処理；非還元ＳＯＳ処理）或いは１００ｔ５分加
熱（後者バッファー処理：還元ＳＯＳ処理）後、５Ｏ３
−ＰＡＧＥに供した。泳動はＳＤＳ−ＰＡＧＥ Ｐｈａ
ｓｔ Ｇｅ１Ｇｒａｄｉｅｎｔ ｇ−２５を用いたＰｈ
ａｓｔ Ｓｙｓｔｅｍ （ファルマシア製電気泳動装置
）で実施した。詳細はファルマシアマニュアルブックに
従った。泳動後、蛋白バンドは銀染色（銀染色キット、
和光製）により検出した。分子量マーカーとしてＰｈｏ
ｓｐｈｏｒｙｌａｓｅＢ（９４Ｋ）、 Ｂｏｖｉｎｅ
ｓｅｒｕｍ ａｌｂｕ＋ｎ１ｎ（６７Ｋ）、 Ｏｖａｌ
ｂｕｍｉｎ（４３Ｋ）、 Ｃａｒｂｏｎｉｃ ａｎｈｙ
ｄｒａｓｅ（３０Ｋ）、 Ｔｒｙｐｓｉｎｉｎｈｉｂｉ
ｔｏｒ（２０，１Ｋ）、 α−Ｌａｃｔｏａｌｂｕｒ
ｎｉｎ（１４，４Ｋ）を用いた。その結果、還元下では
分子量２５にの位置に、また非還元下では分子量２７に
の位置にそれぞれ単一の蛋白バンドが検出された。(4) Properties (i) Molecular weight SDS-PAGE method A part of the differentiation-inducing factor of the present invention (equivalent to about 0.5 μg) was
%SOS, 0.3M 5ucrose content 0.062
5M) Lys-HCl buffer, pH 6, 8, or a buffer containing 2% 2-mercaptoethanol is added to the same buffer and dissolved, and treated with the former buffer for about 30 minutes at room temperature (non-reducing SOS treatment) or heated at 100t for 5 minutes. After (latter buffer treatment: reduction SOS treatment), 5O3
- Subjected to PAGE. The electrophoresis is SDS-PAGE Pha
Ph using st Ge1Gradient g-25
It was carried out using ast System (electrophoresis apparatus manufactured by Pharmacia). Details were in accordance with the Pharmacia Manual Book. After electrophoresis, protein bands are silver stained (silver staining kit,
(manufactured by Wako). Pho as a molecular weight marker
sporylaseB (94K), Bovine
serum albu+n1n (67K), Oval
bumin (43K), Carbonic anhy
drase (30K), Trypsininhibi
tor (20,1K), α-Lactoalbur
nin (14,4K) was used. As a result, a single protein band was detected at a molecular weight of 25 under reduced conditions and at a molecular weight of 27 under non-reduced conditions.
ゲル濾過法
前項（３）（ｊｉ）のゲル濾過法に準じて本発明の分化
誘導因子の分子量を分析したところ、分子量２万〜３万
０持胃に単一ピークとして得られた。Gel filtration method When the molecular weight of the differentiation-inducing factor of the present invention was analyzed according to the gel filtration method described in the previous section (3) (ji), a single peak with a molecular weight of 20,000 to 30,000 was obtained.
（ｊ）等電点
前項（３）（ｉｖ）の等電点クロマト法に準じて、本発
明の分化誘導因子の等電点を分析したところ、等電点ｐ
！は５．４であった。(j) Isoelectric point When the isoelectric point of the differentiation-inducing factor of the present invention was analyzed according to the isoelectric focusing chromatography method in the previous section (3) (iv), the isoelectric point p
! was 5.4.
（ｉｉｉ ）生物学的性状
本発明の分化誘導因子を用いて１１−９３７以外の骨髄
性白血病細胞株（急性骨髄性白血病由来ＭＬ−１細胞及
び急性単球性白血病由来ＴＨＰ−１細胞）二株について
分化誘導能を調べた。その結果ＴＨＰ−１ではＵ−９３
７（ε０５０； ０．２８ｎｇ／ｍｆ）と同程度（ＥＤ
５０； ０．２４ｎｇ／−）のＮＢＴ還元能が認められ
た。一方、ＭＬ−１においては同活性は認められなかっ
た（８０５０； ＞１２５ｎｇ／ｍｌ） 、なお、Ｅ
Ｄ ５０ （ｎｇ／ｍｌ）は５０％吸光度値を示す濃
度を意味する。(iii) Biological properties Two myeloid leukemia cell lines other than 11-937 (acute myeloid leukemia-derived ML-1 cells and acute monocytic leukemia-derived THP-1 cells) were prepared using the differentiation-inducing factor of the present invention. The ability to induce differentiation was investigated. As a result, U-93 in THP-1
7 (ε050; 0.28ng/mf) and the same level (ED
50; 0.24 ng/-) NBT reducing ability was observed. On the other hand, the same activity was not observed in ML-1 (8050; >125ng/ml).
D 50 (ng/ml) means the concentration exhibiting 50% absorbance value.
（ｉｖ）既知サイト力インとの関係
本発明の分化誘導因子のＬｌ−９３７細胞に対するＮＢ
Ｔ還元能（ＤＩＦ活性）は分化誘導能を有することが知
られている既知サイト力イン（ＴＮＦ 、 ＩＦＮ−β
。(iv) Relationship with known cytotoxicity NB of the differentiation-inducing factor of the present invention against Ll-937 cells
T reducing ability (DIF activity) is known to have differentiation-inducing ability (TNF, IFN-β).
.
ｒ 、 Ｐ−１００、ＩＬ−１α、β）に対する抗体で
は全く中和されなかった。r, P-100, IL-1α, β) did not neutralize at all.
（ｖ）Ｎ末端アミノ酸配列
本発明の分化誘導因子４．７μｇを用いて、気相シーク
エンサーにかけ、エドマン分解法によりＮＨ２末端アミ
ノ酸からアミノ酸配列分析を行った。(v) N-terminal amino acid sequence Using 4.7 μg of the differentiation-inducing factor of the present invention, the amino acid sequence was analyzed from the NH2-terminal amino acid using a gas phase sequencer using the Edman degradation method.
その結果、本発明の分化誘導因子はＮ）１２末端Ｖａ１
から始まるシングルポリペプチドであることを確認した
。ＮＨ２末端から１８番目までのアミノ酸配列を以下に
示す。As a result, the differentiation-inducing factor of the present invention is N) 12-terminal Va1
It was confirmed that it is a single polypeptide starting from . The amino acid sequence from the NH2 terminus to the 18th position is shown below.
Ｖａ ＩＰｒｏＰｒｏＧ Ｉ ｙＧ １ｕＡｓｐＳｅｒ
ＬｙｓＡｓｐＶａ ＩＡ ＩａＡ １ａＰｒｏＸＡｒ
ｇＧｌｎＸｌｅｕ−（Ｘは未同定）Va IProProG I yG 1uAspSer
LysAspVa IA IaA 1aProXAr
gGlnXleu- (X is unidentified)
Claims (1)
白質であり、以下の性質を有する分化誘導因子。 （ａ）分子量：２５０００±２０００ （還元下、ＳＤＳ−ＰＡＧＥ法による） （ｂ）等電点：ｐＩ５．４±０．２ （等電点クロマトグラフィーによる） （ｃ）Ｎ末端アミノ酸配列： 【遺伝子配列があります】 （Ｘは未同定） （ｄ）生理活性： 少なくとも、ヒト組織球性リンパ腫由来 の単芽球性株細胞Ｕ−９３７およびヒト急性単球性白血
病株細胞ＴＨＰ−１に対して分化誘導活性を有する。 （ｅ）比活性：５×１０＾６〜１０×１０＾６ｕｎｉｔ
ｓ／ｍｇ蛋白（２）ヒト肺由来線維芽細胞が形質転換さ
れた株化細胞である請求項（１）の分化誘導因子。(1) A differentiation-inducing factor that is a protein present in the culture supernatant of human lung-derived fibroblasts and has the following properties. (a) Molecular weight: 25000±2000 (under reduction, by SDS-PAGE method) (b) Isoelectric point: pI5.4±0.2 (by isoelectric focusing chromatography) (c) N-terminal amino acid sequence: [gene (X is unidentified) (d) Physiological activity: At least differentiated against human histiocytic lymphoma-derived monoblastic cell line U-937 and human acute monocytic leukemia cell line THP-1. Has inducing activity. (e) Specific activity: 5 x 10^6 ~ 10 x 10^6 units
s/mg protein (2) The differentiation-inducing factor according to claim (1), wherein the human lung-derived fibroblasts are transformed cell lines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10019088A JPH01272600A (en) | 1988-04-25 | 1988-04-25 | Differentiation-inducing factor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10019088A JPH01272600A (en) | 1988-04-25 | 1988-04-25 | Differentiation-inducing factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH01272600A true JPH01272600A (en) | 1989-10-31 |
Family
ID=14267382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10019088A Pending JPH01272600A (en) | 1988-04-25 | 1988-04-25 | Differentiation-inducing factor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01272600A (en) |
-
1988
- 1988-04-25 JP JP10019088A patent/JPH01272600A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4490289A (en) | Homogeneous human interleukin 2 | |
| CA1128881A (en) | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells | |
| US4230697A (en) | Virus-inactivated HGI-glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, process for preparing same and leukopenia curative containing same | |
| JPS6030291B2 (en) | HGI glycoprotein that promotes differentiation and proliferation of human granulocytes, method for producing HGI glycoprotein, and therapeutic agent for leukopenia containing HGI glycoprotein | |
| EP0212501B1 (en) | Therapeutic agent for treating hematopoietic diseases | |
| EP0276551A1 (en) | Colony-stimulating factor and method for preparation thereof | |
| NZ203364A (en) | Method for purifying human immune interferon;homogeneous human immune interferon | |
| CA1332149C (en) | Therapeutic agent for thrombocytopenia | |
| JPS63126897A (en) | Immunosuppressive factor | |
| JPH01272600A (en) | Differentiation-inducing factor | |
| EP0516845A1 (en) | Novel megakaryocytic colony stimulating factor and process for its preparation | |
| JPH0296598A (en) | Lymphokine-activating killer cell induction suppressing factor laksf, its production and immunosuppressing agent containing the same factor as active component | |
| EP1006125B1 (en) | Goat epididymal forward motility protein | |
| JPH064675B2 (en) | Antitumor polypeptide | |
| WO1984002912A1 (en) | Protein with oncostatic effect, process for its preparation, and oncostatic drug containing it | |
| JPS62169799A (en) | Substance promoting differentiation and multiplication of macrophage | |
| JPS6030294B2 (en) | Method for heat treatment of fractions containing glycoproteins that promote differentiation and proliferation of human granulocytes | |
| JPS60226816A (en) | Human-originating protein with antitumor activity | |
| JPH022390A (en) | Novel stimulation factor for human granulocyte macrophage colony | |
| JPS63215700A (en) | Low-molecular weight protein | |
| JPS62258324A (en) | Glycoprotein having carcinostatic activity | |
| Bodo | 19. Konferenz der Gesellschaft für Biologische Chemie Purification and Chemical Characterization of Interferon | |
| JPH02100696A (en) | Differentiation-inducing substance derived from human | |
| JPS62169731A (en) | Agent for inducing differentiation of cell | |
| JPH0420289A (en) | Protein |